Optimizing Avidity of Bispecific Drugs
Abstract Bispecific drugs have great potential to improve tissue selectivity through avid binding interactions but…
Certara2024年9月9日
Effects of Tissue Targeting Bispecifics on Therapeutic Window
Abstract Objectives: The presence of target receptors in non-target tissues can reduce the therapeutic window…
Certara2024年9月9日
Optimizing Clinical Development: Saving Time and Costs
Strategic Mechanisticモデリングソリューションは、免疫療法のバイオテクノロジー企業が新規治療法の臨床開発を加速させるのに役立ちます。
Certara2024年8月16日
Application of Quantitative Systems Pharmacology to guide the optimal dosing of COVID-19 vaccines
Optimal use and distribution of coronavirus disease 2019 (COVID-19) vaccines involves adjustments of dosing. Due…
Certara2021年7月31日
Maximizing Oligonucleotide Therapeutic Development: How They Work
This is the first of three blog posts discussing best practices for developing oligonucleotides. Interest…
Certara2021年5月7日
The Promises and Pitfalls of Gene Therapy for Rare Diseases
The state of gene therapy faces much uncertainty as recent regulatory and clinical setbacks have…
Certara2021年4月29日
Getting Gene Therapies to Patients
This blog discusses the challenges that drug developers face in getting patients access to cell…
Certara2021年2月16日
Early Value Assessment in Gene Therapy Clinical Trial Design
A global biotechnology company engineering precision genetic medicine for rare diseases was in need of…
Certara2021年2月12日
8 Tips for Successfully Developing Oligonucleotide Therapies
By Eva Gil Berglund and Nathalie H Gosselin Oligonucleotide therapeutics are a validated class of…
Certara2021年2月1日
